Beyond pain: The surprising connection between tramadol and depression

Background: Tramadol, a centrally acting analgesic with a dual mechanism, is frequently prescribed for pain management, including in cancer patients. However, its association with depression, a multifactorial condition influenced by genetic, biochemical, environmental, and psychosocial factors, requires further elucidation. Objective: This study aims to investigate the potential link between tramadol exposure and depression through a comprehensive analysis of pharmacovigilance data and Mendelian randomization methods. Methods: We conducted a retrospective analysis using the FDA Adverse Event Reporting System (FAERS) database, focusing on reports from Q1 2004 to Q1 2023. Data from the EBI and UK Biobank databases were also utilized. Disproportionate analysis methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN), were applied to evaluate the relationship between tramadol and depression. Mendelian randomization was performed using the “TwoSampleMR” package in R software to assess the causal relationship. Results: The pharmacovigilance analysis revealed that mental disorders were the most frequently reported adverse events associated with tramadol use, with a significant positive association between tramadol and depression reports (ROR 1.34, 95% CI 1.25–1.44; PRR 1.34, 95% CI 1.26–1.43). Mendelian randomization analysis indicated a significant positive correlation between tramadol exposure and depression (P (IVW) = 0.01). At the same time, our comparative analysis of the risk of depression between tramadol and other opioids found that tramadol was more associated with depression risk than other opioids. Multivariate Mendelian randomization results showed that a causal relationship between tramadol and depression remained when chronic pain was considered an important confounder. Conclusion: The association between tramadol use and depression has significant clinical implications for patient safety and the optimization of treatment strategies. Future research should explore the impact of tramadol on the neurotransmitter system and its efficacy and safety in different subpopulations of patients with depression.